European nations must stop prescribing old drugs to treat HBV - Study

19 August 2015

European countries need to discontinue prescribing older, suboptimal drugs to treat hepatitis B virus (HBV) as the virus has become drug resistant, a new study shows.

According to the results of the study published in The Journal of Infectious Diseases, doctors in Europe have been prescribing old antiviral drugs, which in turn is also likely to result in creating resistance to modern compounds. The report has called for putting a stop to prescribing nucleos(t)ide analogues (NAs) as the only way to end the development of drug-resistant hepatitis B virus.

Older NAs are still being prescribed in European countries in face of limited access to newer NAs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK